Easy and low-cost identification of metabolic syndrome in patients treated with second-generation antipsychotics: Artificial neural network and logistic regression models

Journal of Clinical Psychiatry

Volumn 71, Issue 3, 2010, Pages 225-234

  Lin, Chao Cheng ^a,c   Bai, Ya Mei ^d,e   Chen, Jen Yeu ^f   Hwang, Tzung Jeng ^c   Chen, Tzu Ting ^f   Chiu, Hung Wen ^b   Li, Yu Chuan ^b,g  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f YULI VETERANS HOSPITAL   (Taiwan)

^g NONE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; ARTIFICIAL NEURAL NETWORK; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIASTOLIC BLOOD PRESSURE; DRUG COMBINATION; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTHROPOMETRY; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, STATISTICAL; NEURAL NETWORKS (COMPUTER); PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; WAIST CIRCUMFERENCE;

EID: 77950326901     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04628yel     Document Type: Article

References (49)

1. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159(6):1018- 1028.
2. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361(9369):1581-1589.
3. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57(3):249-258.
4. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3)414-425.
5. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162(5):947-953.
6. Rettenbacher MA. Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics. Curr Opin Psychiatry. 2005;18(2): 175-179.
7. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. J Clin Psychiatry. 2007;68(suppl 6):14-23.
8. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68 (suppl 1):20-27.
9. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83(1):87-93.
10. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32.
11. Saari KM, Lindeman SM, Viilo KM. et at. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry. 2005;66(5):559-563.
12. Bai YM, Chen JY, Yang WS, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry. 2007;68(12):1834-1839.
13. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med. 2001;111(9):716-723.
14. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22(7):841-852.
15. Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003;23(6):735-744.
16. Peuskens J, De HM, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol. 2007;22( 3): 145-152.
17. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159(4):561-566.
18. Hosojima H, Togo T, Odawara T, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol. 2006;20(1):75-79.
19. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv. 2003;54(4):565-567.
20. Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol. 2002;17(4):145-160.
21. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66(1):51-57.
22. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11-53.
23. Dalmau A, Bergman B, Brismar B. Somatic morbidity in schizophrenia - a case control study. Public Health. 1997;111:393-397.
24. Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001;62(suppl 7):32-37.
25. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(suppl 7):22-31.
26. Marder SR. Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334-1349.
27. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry. 2006;51(8):492-501.
28. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1-3):15-22.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
30. International Diabetes Federation. Worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/MetS-def-update2006.pdf. Accessed August 27, 2009
31. Dreiseitl S, Ohno-Machado L. Logistic regression and artificial neural network classification models: a methodology review. J Biomed Inform. 2002;35(5-6):352-359.
32. Subasi A, Ercelebi E. Classification of EEG signals using neural network and logistic regression. Comput Methods Programs Biomed. 2005;78(2):87-99.
33. Tourassi GD, Floyd CE. The effect of data sampling on the performance evaluation of artificial neural networks in medical diagnosis. Med Decis Making. 1997;17(2):186-192.
34. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29-36.
35. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839-843.
36. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21(11):911-936.
37. Politi E, Franchini L, Spagnolo C, et al. Supporting tools in psychiatric treatment decision-making: sertraline outcome investigation with artificial neural network method. Psychiatry Res. 2005;134(2):181-189.
38. Franchini L, Spagnolo C, Rossini D, et al. A neural network approach to the outcome definition on first treatment with sertraline in a psychiatric population. Artif Intell Med. 2001;23(3):239-248.
39. Serretti A, Smeraldi E. Neural network analysis in pharmacogenetics of mood disorders. BMC Med Genet. 2004;5:27.
40. Lin CC, Wang YC, Chen JY, et al. Artificial neural network prediction of clozapine response with combined pharmacogenetic and clinical data. Comput Methods Programs Biomed. 2008;91(2):91-99.
41. Das A, Ben-Menachem T, Cooper GS, et al. Prediction of outcome in acute lower-gastrointestinal haemorrhage based on an artificial neural network: internal and external validation of a predictive model. Lancet. 2003;362(9392):1261-1266.
42. McNeil BJ, Keller E, Adelstein SJ. Primer on certain elements of medical decision making. N Engl J Med. 1975;293(5):211-215.
43. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49(11):753-760.
44. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356(9246):1955-1964.
45. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338(21):1516-1520.
46. Chen CH, Chiu CC, Huang MC, et al. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(4):925-931.
47. Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res. 2006;83(1):95-101.
48. Haydon GH, Jalan R, la-Korpela M, et al. Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors. J Viral Hepat. 1998;5(4)255-264.
49. Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetis Obes Metab. 2006;8(2):125-135